secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEOGENOMICS INC (NEO)
CIK:        0001077183
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001077183-23-000019
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeoGenomics Q4 revenue up 10% to $139M; net loss narrows to $23M; issues 2023 guidance with improved EBITDA
--------------------------------------------------------------------------------

- Q4 revenue $139M (+10% YoY); full year revenue $510M (+5% YoY).
- Q4 net loss $23M vs $42M loss in Q4 2021; full year net loss $144M vs $8M loss in 2021 (2021 included $109M Inivata gain).
- Q4 adjusted EBITDA -$1.2M vs -$10M in Q4 2021; full year adjusted EBITDA -$48M vs -$4M in 2021.
- 2023 guidance: revenue $545-555M (7-9% growth), adjusted EBITDA $(27)-$(22)M (44-54% improvement).
- Cash and marketable securities $438M at quarter end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1077183/000107718323000019/0001077183-23-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1077183/000107718323000019/neo-20230223.htm
  HTML page:      https://secwatch.observer/filing/0001077183-23-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer